Atea Pharmaceuticals, Inc. (AVIR), a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies, is on track to report topline results from its phase II combination program in a hepatitis C virus (HCV) trial early this month.
The hepatitis C virus (HCV) causes Hepatitis C, a liver disease that often presents no symptoms, leading many individuals to remain unaware that they have it. If not treated, hepatitis C can result in serious liver damage, such as scarring (cirrhosis) and potentially liver cancer.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.